Demonstrating real-world effectiveness in allergy immunotherapy – the REACT case study
CME accredited
December 14, 15:00 CET
Leaders in allergy and respiratory medicine, as well as real world evidence, discuss the state of RWE in AIT research include:
Register for the webinar now – fill in your details on the right >>>
The revolutionary potential of real-world evidence (RWE) has been much discussed this last decade. However, up until now the progress of RWE has been limited – with frustration in some communities rising due to lack of cross-industry understanding, investment, and regulatory ambition – all needed to drive the real change needed.

Within the field of respiratory allergy, exploring the long-term and sustained effectiveness of allergy immunotherapy is of great clinical relevance, as allergy immunotherapy is the only causal treatment option.   

In our latest CME accredited webinar, we’re bringing together leaders to explore the current state of RWE in AIT research. You will gain insight into the existing impact on clinicians, what the key considerations are when considering RWE versus traditional RCT approaches, and how to overcome common RWE pitfalls. We will then deep dive into the REACT case study to show you novel approaches to designing RWE studies in the AIT space, and how this study impacted the existing research understanding.
Key learnings include:
  • The current state of play of real-world evidence (RWE) in AIT research and clinical practice – why EAACI have called for action
  • How RWE can be used to compliment clinical studies, the key differences in objectives and design   
  • Conduct high-quality RWE studies in AIT – strategies to overcome common pitfalls such as ensuring full transparency, pre-specified outcomes, and proxy use
  • Deep dive into the REACT case study: explore the scientific methodology, study design, and impact of the findings on our existing AIT understanding
  • The future of RWE studies in AIT – impact of regulatory policy and big data initiatives
Fill out your details on the right to register for the CME accredited webinar>>>
Following the recording of this webinar, the REACT paper has been published in The Lancet Regional Health – Europe journal -  Fritzsching B, et al.
Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: results from the REACT study, a retrospective cohort study
The Lancet Regional Health – Europe. 2021; 10.1016/j.lanepe.2021.100275
Accreditation Statement and Credit Designation
European Accreditation Council for Continuing Medical Education (UEMS/EACCME)

The Real-world effectiveness in allergy immunotherapy – the REACT study webinar is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS):

The Real-world effectiveness in allergy immunotherapy – the REACT study webinar is designated for a maximum of, or up to, 1 European external CME credit. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. 

American Medical Association (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at

Royal College of Physicians and Surgeons of Canada

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit:
Educational Objectives
After participating in this educational event, learners should be able to:

  • Address individual needs in compliance with their Continuous Professional Development (CPD) plan
  • Identify what does REACT adds of novel insights to the understanding of AIT
  • Discuss RWE in AIT
  • Describe differences between RWE studies & RCTs
  • Discuss REACT study design and key results
  • Identify how to conduct high-quality RWE studies in AIT
Target Audience  
The webinar is targeting health care professionals in the field of allergy immunotherapy.
To Receive Your CME/CPD Certificate  
The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

Before 14 March 2022:

1. Access the online system via any of the following

2. Complete the anonymous online evaluation

3. Complete the credit claim form and submit

4. The CME/CPD certificate will be available for download; retain for your personal records
Disclosure and Resolution of Personal Conflicts of Interest 
In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated, and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event. 

Disclosure information is available here
Kind regards,
Register for the webinar now!

Fill in your details to get access to this CME accredited webinar.
Reuters Events will use this information to contact you about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy:
Please tick this box to give Reuters Events permission to provide my contact information to ALK - and its affiliates so ALK can share the latest ALK news and offers with me by email or telephone.
You may unsubscribe from receiving news and offers from the sender at any time by following the instructions in the communications received. ALK handles your information as described in the ALK Privacy Notice -

Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.